Mustang Bio Establishes CAR T Cell Therapy Manufacturing Facility in Massachusetts – Nasdaq
|
Mustang Bio Establishes CAR T Cell Therapy Manufacturing Facility in Massachusetts
Nasdaq The facility is expected to be operational for the production of personalized CAR T therapies in 2018. Mustang anticipates initially building cell-processing capabilities to support its lead CAR T product candidates MB-101 in glioblastoma, and MB-102 … |
